On March 6, Lbx Pharmacy Chain Joint Stock Company(603883) ( Lbx Pharmacy Chain Joint Stock Company(603883) ) disclosed that the company planned to purchase 719643% of the equity of Hunan Huairen Great Health Industry Development Co., Ltd. (hereinafter referred to as “Huairen great health”) held by 14 counterparties such as Lin Chengxiong and Chen Jianping with its own funds of 1.637 billion yuan (including loans).
Lbx Pharmacy Chain Joint Stock Company(603883) said that before the completion of this transaction, the company held 4.1556% equity of Huairen dahealth, and after the completion of this transaction, the company will hold 761199% equity of Huairen dahealth.
The announcement shows that the counterparty has also made performance commitments, promising that the net profit of Huairen dahealth in 2022 (referring to the net profit attributable to the shareholders of the parent company after deducting non recurring profits and losses through audit) will not be less than 110 million yuan, the net profit in 2023 will not be less than 131 million yuan, the net profit in 2024 will not be less than 152 million yuan, and the average annual compound growth rate of performance from 2021 to 2024 will be about 20.17%.
